Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Ear Nose Throat J ; 100(7): 546-551, 2021 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-31581834

RESUMEN

INTRODUCTION: Incidental papillomas of the pharynx can be found while examining the nasopharynx, oropharynx, and hypopharynx for other disorders of the head and neck. Purpose of the study is to explore the location, biopsy protocol, and decision to perform office-based versus operative management via potassium titanyl phosphate (KTP) laser when an oropharyngeal papilloma is discovered incidentally. METHODS: A retrospective review of the senior author's patient population was performed using Current Procedural Terminology and/or International Classification of Diseases codes to identify patients who had KTP laser removal of incidental oropharyngeal papillomas. Patients were included based on the incidental nature of the papilloma and confirmed pathology report of squamous papilloma. Demographics, presenting complaint, lesion location, pathological analysis, type of intervention, and outcomes were recorded. When available, human papillomavirus (HPV) subtype was noted. RESULTS: A total of 26 cases were identified, 13 females and 13 males. The median age at time of surgery was 58 years (range: 21-77). The most common presenting symptoms were difficulty swallowing and throat pain. The most common locations were the base of tongue, uvula, tonsils, and the soft palate. Of the 26 patients, 23 patients received KTP laser ablation therapy as an office-based procedure, while the remaining 3 were performed under general anesthesia in the operating room. Only 5 patients had a recorded recurrence that required reoperation. There were no operative or postoperative complications. There were 16 biopsy samples tested for HPV, where 12 were negative for HPV and 4 were positive for HPV. CONCLUSION: Oropharyngeal papillomas, when present, can be found incidentally during examination of the oropharynx for other symptoms. Office-based biopsy and KTP laser is a safe and efficient means of identifying and removing most oropharyngeal papillomas.


Asunto(s)
Toma de Decisiones Clínicas/métodos , Trastornos de Deglución/diagnóstico , Neoplasias Orofaríngeas/diagnóstico , Orofaringe/cirugía , Papiloma/diagnóstico , Adulto , Anciano , Procedimientos Quirúrgicos Ambulatorios , Biopsia , Trastornos de Deglución/etiología , Trastornos de Deglución/cirugía , Femenino , Humanos , Hallazgos Incidentales , Láseres de Estado Sólido/uso terapéutico , Masculino , Persona de Mediana Edad , Neoplasias Orofaríngeas/complicaciones , Neoplasias Orofaríngeas/cirugía , Orofaringe/patología , Papiloma/complicaciones , Papiloma/cirugía , Estudios Retrospectivos , Adulto Joven
2.
Am J Otolaryngol ; 41(5): 102552, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32505990

RESUMEN

BACKGROUND: Salivary fistulas remain a significant problem in patients undergoing major head and neck reconstructive surgery. Surgical sealants have become increasingly used in cutaneous and non-cutaneous wound closure, providing a barrier to fluids/gases and promoting healing. The purpose of this study was to determine the efficacy of a common surgical sealant, 2-Octyl Cyanoacrylate (2-OCA, Dermabond®), in the prevention of salivary fistulas following free flap reconstruction of the oral cavity. METHODS: In this non-randomized, single arm prospective trial, patients undergoing free flap reconstruction of gravity-dependent oral cavity defects were recruited. Application of 2-OCA was performed along flap inset suture lines at the time of surgery. Prospectively collected trial data were propensity score matched to a control cohort to compare outcomes. Data collected include demographics, medical co-morbidities, previous treatments, primary tumor site, and subsites reconstructed. The primary outcome measure was rate of salivary fistula formation. Secondary outcomes were time to development of leak and percentage of patients tolerating oral feeding at one month post-operatively. RESULTS: In the 46 propensity score matched pairs, eight (17.4%) out of 46 patients in the 2-OCA prospective cohort and seven (15.2%) out of 46 patients in the control cohort developed postoperative salivary fistulas within the one-month study interval (p = 1.00). The average time to postoperative leak in the 2-OCA group was 12.5 days versus 7.1 days in the control cohort (p = 0.10). In the 2-OCA group, 30 (65.2%) patients were tolerating regular diet at one month post-operatively compared to 33 (71.7%) in the control cohort (p = 0.65). CONCLUSION: Salivary fistula rates after application of a 2-OCA surgical sealant were not improved compared to a control cohort in this single institutional trial. There are several surgical sealants available, each with varying elasticity and adhesiveness. Future studies are needed to identify surgical sealants that are able to provide sufficient strength and adhesion to seal closures and combat corrosive saliva, but elastic enough to handle motion related tension during swallowing and post-operative movements in the head and neck.


Asunto(s)
Cianoacrilatos/administración & dosificación , Colgajos Tisulares Libres , Boca/cirugía , Resultados Negativos , Procedimientos Quirúrgicos Orales/métodos , Procedimientos de Cirugía Plástica/métodos , Complicaciones Posoperatorias/prevención & control , Fístula de las Glándulas Salivales/prevención & control , Adhesivos Tisulares/administración & dosificación , Anciano , Estudios de Cohortes , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos
3.
Laryngoscope ; 128(7): 1515-1517, 2018 07.
Artículo en Inglés | MEDLINE | ID: mdl-29314082

RESUMEN

Human papillomavirus-related carcinoma with adenoid cystic-like features is a newly described histologic variant of sinonasal tract carcinoma. The implications of this sinonasal malignancy is still being evaluated. There are a limited number of cases reported in the literature, and thus we seek to further characterize this patient population and review the histologic features of this malignancy with the following two cases. The behavior of this entity is as yet uncertain. Laryngoscope, 128:1515-1517, 2018.


Asunto(s)
Carcinoma Adenoide Quístico/patología , Neoplasias Nasales/patología , Infecciones por Papillomavirus/complicaciones , Carcinoma Adenoide Quístico/cirugía , Carcinoma Adenoide Quístico/virología , Humanos , Masculino , Persona de Mediana Edad , Nariz/patología , Neoplasias Nasales/cirugía , Neoplasias Nasales/virología , Papillomaviridae/genética , Estudios Prospectivos
5.
Curr Opin Otolaryngol Head Neck Surg ; 25(4): 326-331, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28504985

RESUMEN

PURPOSE OF REVIEW: The purpose of this manuscript is to review the current literature regarding the management of frontal sinus fractures and offer the authors opinion on the current management of these traumatic injuries. We evaluate recently proposed management algorithms as well as novel surgical approaches reported within the last few years. RECENT FINDINGS: Patient selection for sinus sparing treatment modalities is balanced between fracture severity, involved structures, and reliable patient surveillance. Minimally invasive, aesthetically favorable approaches grow in diversity for anterior table fractures. For fractures of the posterior sinus wall and nasofrontal outflow tract, the literature focuses on sinus sparing surgery, as well as better defining the patients in which obliteration and/or cranialization is appropriate. SUMMARY: Lack of large patient cohorts and follow-up limits generalizability of frontal sinus fracture research, and the ability to develop national guidelines of management. Evidence-based literature shows growing support for conservative management and sinus preservation. Improvements in frontal sinus fracture classification schemes, surgical technique, and patient selection direct this treatment paradigm shift.


Asunto(s)
Fijación de Fractura/métodos , Seno Frontal/lesiones , Otolaringología , Fracturas Craneales/cirugía , Algoritmos , Seno Frontal/cirugía , Humanos , Tratamientos Conservadores del Órgano/métodos , Tomografía Computarizada por Rayos X
6.
Clin Lymphoma Myeloma Leuk ; 14(6): 480-4, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25176474

RESUMEN

INTRODUCTION: This study evaluated the safety and efficacy of radiotherapy (RT) with concurrent novel agents (NAs), cytotoxic therapy (CTx), or both in the management of osteolytic bone lesions in multiple myeloma (MM). PATIENTS AND METHODS: A total of 39 patients with MM received RT to 64 different bone sites during the 2007-2012 period, with a dose of 8 to 37.5 Gy (mean, 26.8 Gy) delivered in 1 to 15 fractions (median, 10 fractions). Of these patients, 21 also received concurrent NAs or CTx. Pain response, M protein and κ light chain response, and adverse events were evaluated. RESULTS: RT was completed in 35 of 39 patients (89.7%) in this study. Pain relief was observed in 30 of 31 patients (96.7%). Hematologic toxicity (grade 3 or 4 by the Radiation Therapy Oncology Group system) was seen in 43.2% of treated patients, and NA therapy was stopped in 2 patients owing to grade 4 toxicity. RT adverse effects resolved at 4 to 6 weeks posttreatment. Changes in pre- and posttreatment levels of M protein trended toward significance in patients treated with RT + systemic therapy (ST) versus. RT alone (ΔM ProteinRT+ST = 5.6 g/L; ΔM ProteinRT = 0 g/L; P = .089). CONCLUSION: Treating MM with RT concurrently with CTx including NAs was safe and well tolerated in the majority of patients (14 of 16 [87.5%] for those taking NAs and 19 of 21 [90.5%] for all patients). Excellent clinical pain response (> 95%) was also seen in patients regardless if they were treated with RT + ST or RT alone.


Asunto(s)
Mieloma Múltiple/terapia , Adulto , Anciano , Anciano de 80 o más Años , Trasplante de Médula Ósea , Quimioradioterapia/efectos adversos , Terapia Combinada , Femenino , Humanos , Cadenas kappa de Inmunoglobulina/sangre , Masculino , Persona de Mediana Edad , Mieloma Múltiple/sangre , Mieloma Múltiple/patología , Estadificación de Neoplasias , Dosificación Radioterapéutica , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...